Abstract
Oxprenolol (OX) is a nonselective, β-adrenergic blocking agent with intrinsic sympathomimetic activity. We studied 178 patients in five centers to determine whether a polymer-matrix-based, slow-release preparation of oxprenolol (SR-OX) given once daily was as effective as the standard preparation given twice daily for the treatment of patients with mild to moderate hypertension. After a placebo washout phase, patients were treated with OX until blood pressure was controlled. They were then randomized in a double-blind fashion to continue the same dose, given as either OX bid or SR-OX qd with a placebo as the second dose. All patients took hydrochlorothiazide 50-100 mg/d throughout the study. Blood pressure was reduced 23/15 mm Hg (p < 0.001) and pulse 8 beats/min in the SR-OX group (n = 67), and 24/17 mm Hg (p < 0.001) and 8 beats/min in the OX group (n = 72) by titrating standard OX. After randomization to SR-OX or OX, there were no further changes over six weeks. Home-determined blood pressures showed no loss of control in the evening. There were no unexpected adverse effects. We conclude that SR-OX given once daily is as effective as OX given twice daily for the treatment of hypertension.
| Original language | English |
|---|---|
| Pages (from-to) | 51-54 |
| Number of pages | 4 |
| Journal | Drug Intelligence and Clinical Pharmacy |
| Volume | 17 |
| Issue number | 1 |
| State | Published - Feb 14 1983 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Pharmacology (medical)
- Pharmacology, Toxicology and Pharmaceutics(all)
Cite this
Slow-release oxprenolol compared with oxprenolol in hypertensive patients : A multicenter clinical trial. / Materson, Barry J; Friedman, B. A.; Hla, K. M.; Neidorf, B. S.; Gray, J. M.; Glazer, N.; Gross, S.
In: Drug Intelligence and Clinical Pharmacy, Vol. 17, No. 1, 14.02.1983, p. 51-54.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Slow-release oxprenolol compared with oxprenolol in hypertensive patients
T2 - A multicenter clinical trial
AU - Materson, Barry J
AU - Friedman, B. A.
AU - Hla, K. M.
AU - Neidorf, B. S.
AU - Gray, J. M.
AU - Glazer, N.
AU - Gross, S.
PY - 1983/2/14
Y1 - 1983/2/14
N2 - Oxprenolol (OX) is a nonselective, β-adrenergic blocking agent with intrinsic sympathomimetic activity. We studied 178 patients in five centers to determine whether a polymer-matrix-based, slow-release preparation of oxprenolol (SR-OX) given once daily was as effective as the standard preparation given twice daily for the treatment of patients with mild to moderate hypertension. After a placebo washout phase, patients were treated with OX until blood pressure was controlled. They were then randomized in a double-blind fashion to continue the same dose, given as either OX bid or SR-OX qd with a placebo as the second dose. All patients took hydrochlorothiazide 50-100 mg/d throughout the study. Blood pressure was reduced 23/15 mm Hg (p < 0.001) and pulse 8 beats/min in the SR-OX group (n = 67), and 24/17 mm Hg (p < 0.001) and 8 beats/min in the OX group (n = 72) by titrating standard OX. After randomization to SR-OX or OX, there were no further changes over six weeks. Home-determined blood pressures showed no loss of control in the evening. There were no unexpected adverse effects. We conclude that SR-OX given once daily is as effective as OX given twice daily for the treatment of hypertension.
AB - Oxprenolol (OX) is a nonselective, β-adrenergic blocking agent with intrinsic sympathomimetic activity. We studied 178 patients in five centers to determine whether a polymer-matrix-based, slow-release preparation of oxprenolol (SR-OX) given once daily was as effective as the standard preparation given twice daily for the treatment of patients with mild to moderate hypertension. After a placebo washout phase, patients were treated with OX until blood pressure was controlled. They were then randomized in a double-blind fashion to continue the same dose, given as either OX bid or SR-OX qd with a placebo as the second dose. All patients took hydrochlorothiazide 50-100 mg/d throughout the study. Blood pressure was reduced 23/15 mm Hg (p < 0.001) and pulse 8 beats/min in the SR-OX group (n = 67), and 24/17 mm Hg (p < 0.001) and 8 beats/min in the OX group (n = 72) by titrating standard OX. After randomization to SR-OX or OX, there were no further changes over six weeks. Home-determined blood pressures showed no loss of control in the evening. There were no unexpected adverse effects. We conclude that SR-OX given once daily is as effective as OX given twice daily for the treatment of hypertension.
UR - http://www.scopus.com/inward/record.url?scp=0020683196&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0020683196&partnerID=8YFLogxK
M3 - Article
VL - 17
SP - 51
EP - 54
JO - Annals of Pharmacotherapy
JF - Annals of Pharmacotherapy
SN - 1060-0280
IS - 1
ER -